Platelet function testing in uraemic patients

Hematology

Volumn 13, Issue 1, 2008, Pages 49-58

  Ho, Shir Jing ^a   Gemmell, Rosalie ^a   Brighton, Timothy A ^b  

^a ST GEORGE HOSPITAL   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

PFA 100; Platelet function testing; Skin bleeding time (SBT); Uraemic platelet dysfunction

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATININE; UREA;

ACUTE KIDNEY FAILURE; ANALYZER; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CELL COUNT; BLOOD TRANSFUSION; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INTERMETHOD COMPARISON; KIDNEY BIOPSY; LABORATORY TEST; LOW DRUG DOSE; MALE; NEPHROTIC SYNDROME; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RENAL REPLACEMENT THERAPY; SKIN BLEEDING TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; UREA BLOOD LEVEL; UREMIA; BLOOD; PROSPECTIVE STUDY; THROMBOCYTE ADHESIVENESS;

BLEEDING TIME; COHORT STUDIES; CREATININE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PROSPECTIVE STUDIES; THROMBELASTOGRAPHY; UREMIA;

EID: 48449095626     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453308X315834     Document Type: Article

References (43)

1. Morgagni GB. Opera Omnia, in quinque tomos divisa, quorum operum qu antea,et ubi, et qu nun sint edita, prfatio ostendent. Venice: Veretiis ex typographia Remondiniae, 1764.
2. Bright R. Tabular view of the morbid appearance in 100 cases connected with albuminous urine: With observations. Guy's Hosp Rep 1836; 1: 380-400.
3. Weigert AL, Schafer AI. Uremic Bleeding: Pathogenesis and Therapy. Am J Med Sc 1998; 316(2): 94-104.
4. Rao AK. Acquired disorders of platelet function. In: Michelson AD (ed). Platelets. Amsterdam: Elsevier Science, 2002; 701-727.
5. Remuzzi G. Bleeding in renal failure (review) Lancet 1988; 1: 1205-1208
6. Noris M, Remuzzi G. Uremic bleeding: Closing the circle after 30 years of Controversies? Blood 1999; 94(8): 2569-2574.
7. Rabiner SF, Molinas F. The role of phenol and phenolic acids on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am J Med 1970; 49: 346-351.
8. Horowitz HI, Stein IM, Cohen BD, White JG. Further studies on the platelet inhibitory effect of guanidine succinic acid and its role in uremic bleeding. Am J Med 1970; 49: 336-345.
9. Castaldi PA, Rozenberg MC, Stewart JH. The bleeding disorder of uraemia. A qualitative platelet defect. Lancet 1996; ii 66.
10. Eknoyan G, Wacksman SJ, Glueck H, Will JJ. Platelet function in renal failure. N Engl J Med 1969; 280(13): 677-681.
11. Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972; 287(4): 155-159.
12. Steiner RW, Coggins C, Carvalho A. Bleeding time in uraemia a useful test to assess clinical bleeding. Am J Hematol,1979; 7: 107-117.
13. Mannucci PM, Remuzzi G, Pusineri F, Zimmerman TS, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uraemia. N Engl J Med 1983; 308(1): 8-12.
14. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. J Am Soc Hematol 1997; 90(7): 2515-2521.
15. Livio M, Remuzzi G, Marchesi D, Gaetano G, et al. Uraemic bleeding: Role of anaemia and beneficial effect of red cell transfusions. Lancet 1982; 2: 1013-1015.
16. Holloway DS, Vagher JP, Caprini JA, et al. Thromboelastography of blood from subjects with chronic renal failure. Thromb Res 1987; 45(6): 817-25
17. Gawaz MP, Dobos G, Spath M, et al. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 1994;5:36-46
18. Orsende JI, Fuster V, Eli I, Varon D, Badimon JJ, et al. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests. Relevance for monitoring long-term Glycoprotein IIb/IIIa inhibition. Circulation 2001; 103: 1488-1491
19. Mielke CH. Measurement of the bleeding time. International Committee Communications. Thromb Haemost 1984; 52(2): 210-211.
20. Refaai MA, Laposta M. Platelet aggregation. In: Michelson AD (ed.). Platelets. San Diego: Academic Press; 2004; 291-296.
21. Kenet G, Lubetsky A, Shenkman B, Varon D, et al. Cone and platelet analyzer (CPA): A new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998; 101: 255-259.
22. Rodgers RPC, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16: 1-20.
23. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991; 77: 2547-2552.
24. Mattix H, Singh AK. Is the bleeding time predictive of bleeding prior to a percutaneous renal biopsy? Curr Opin Nephrol Hypertens 1999; 8: 715-718.
25. Lehman CM, Blaylock RC, Alexander DP, Rodgers GM. Discontinuation of the bleeding time test without detectable adverse clinical impact. Clin Chem 2001; 47(7): 1204-1211.
26. O'Laughlin JC, Hoftiezer JW, Mahoney JP, Ivey KJ. Does aspirin prolong bleeding from gastric biopsies in man? Gastrointest Endosc 1981; 27: 1-5.
27. MacDonald JD, Remington BJ, Rodgers GM. The skin bleeding time test as a predictor of brain bleeding time in a rat model. Throm Res 1994; 76: 535-540.
28. Royal College of Pathologists of Australia (RCPA) manual, 4th Edition. www.rcpamanual.edu.au.
29. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: A new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24: 195-202.
30. Jilma B. Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 152-163.
31. R for assessing bleeding disorders and monitoring therapy: A review of analytical variables, benefits and limitations. Haemophilia 2001; 7: 170-179
32. Haubelt H, Anders C, Vogt A et al. Variables influencing Platelet Function Analyzer-100™ closure times in healthy individuals. Br J Haematol 2005; 130: 759-767.
33. Francis JL. Platelet function analyzer (PFA-100). In: Michelson AD, (ed). Platelets. San Diego: Academic Press, 2004; 325-335.
34. Escolar G, Cases A., Vinas M et al. Evaluation of acquired platelet dysfunction in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): Influence of hematocrit elevation. Haematologica 1999; 84: 614-619.
35. Zupan IP, Sabovic M, Ponikvar J, et al. Utility of in vitro closure time test for evaluation platelet-related primary hemostasis in dialysis patients. Am J Kidney Dis 2003; 42(4): 744-751.
36. Harrison P. The role of PFA-100® testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005; 130: 3-10.
37. Hayward CPM, Harrison P, Cattaneo M, et al. Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312-319.
38. Harrison P. Measuring platelet function? Hematol J 2004; 5,S164-S169.
39. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000; 111: 733-744.
40. Varon D, Savion N. Cone and platelet analyzer. In: Michelson AD (ed). Platelets. Amsterdam: Elsevier Science, 2002; Ch. 23
41. Varon D, Dardi R, Tamarin I, Savion N, et al. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997; 85(4): 283-294.
42. Peerschke E, Silver RS, Weksler B, Varon D, et al. Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and platelet analyzer:eFfect of platelet antagonists. Br J Haematol 2004; 127: 195-203.
43. Pivalizza EG, Abramson DC, Harvey A. Perioperative hypercoagulability in uremic patients: A viscoelastic study. J Clin Anesth 1997; 9(6): 442-445.